ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, announces a strategic investment from Catalio Capital Management, L.P. to accelerate the global expansion of its technology-enabled sleep health platform. Under the agreement, Catalio, a premier healthcare-focused investment firm, has committed up to $38 million to advance development of next-generation remote patient monitoring (RPM) and proprietary sleep diagnostic devices, fund comparative clinical studies, and scale the infrastructure needed to meet surging demand for patient-preferred OSA therapies.
Read the full article: ProSomnus Secures $38M Strategic Investment from Catalio Capital Management to Scale Smart Sleep Medicine™ //
Source: https://www.businesswire.com/news/home/20260218722060/en/ProSomnus-Secures-%2438-Million-Strategic-Investment-from-Catalio-Capital-Management-to-Scale-Smart-Sleep-Medicine